Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)
Funding Amount
Not stated
Deadline
Forecast — dates not yet posted
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Public & Indian housing authorities
- County governments
- Nonprofits (501(c)(3))
- Tribal governments
- For-profit businesses
- Special district governments
- State governments
- City & township governments
Geography
- Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Overview
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to continue to support the Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium, which coordinates research on prevention, diagnosis, treatment, and mechanisms of resistance in SCLC. The CC manages administrative activities, centralized databases, tissue banking and a virtual biospecimen resource, biostatistics and bioinformatics support, in vivo and in vitro model repositories, and communications and website operations for the Consortium. Since its establishment in response to the Recalcitrant Cancer Research Act, the Consortium has catalyzed SCLC-focused research and enabled major advances in molecular characterization, tumor heterogeneity, microenvironment and immune evasion, biomarker development, preclinical models, therapeutic strategies, and clinical translation. The current U24 CC, based at Sloan Kettering with collaborating institutions, organizes meetings, maintains extensive -omics and model resources, supports young investigators, and provides datasets and models to the research community. The reissue NOFO will support a five-year cooperative agreement to sustain these shared resources and collaborations. This is a Forecast for a single source that will invite application(s) from eligible organization(s) to apply. Please see the Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-27-009
- Instrument: cooperative_agreement
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Focus Areas & Funding Uses
Fields of Work
- Cancer
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health
Amount
Varies
Deadline
October 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed). Now let's win it.